or Try an Advanced Search...

    Technical Analysis for ATXS - Astria Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 9.75 1.77% 0.17
    ATXS closed down 1.74 percent on Wednesday, November 20, 2024, on 81 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical ATXS trend table...
    Date Alert Name Type % Chg
    NR7 Range Contraction 1.77%
    Lower Bollinger Band Walk Weakness 1.77%
    Inside Day Range Contraction 1.77%
    Wide Bands Range Expansion 1.77%
    Lower Bollinger Band Touch Weakness 1.77%
    Oversold Stochastic Weakness 1.77%
    Slingshot Bearish Bearish Swing Setup 0.00%
    Bullish Engulfing Bullish 0.00%
    Pocket Pivot Bullish Swing Setup 0.00%
    Lower Bollinger Band Walk Weakness 0.00%
    Older End-of-Day Signals for ATXS ...

       Recent Intraday Alerts

    Alert Time
    Rose Above Previous Day's High 20 minutes ago
    Up 2% 29 minutes ago
    Up 1% about 1 hour ago
    60 Minute Opening Range Breakout about 1 hour ago
    Down 3% about 4 hours ago
    View Earlier Intraday Alerts

    Free Daily (Stock) Chart Reading

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    ATXS Chart by TradingView
    Basic chart:

    Profile

    Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Biopharmaceutical Clinical Medicine Life Sciences Immunology Monoclonal Antibody Antibody Angioedema Hereditary Angioedema Kallikrein Complement Deficiency

    Is ATXS a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 13 Astria TherapeuticS GAAP EPS of -$0.42 in-line
    Nov 13 Astria Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
    Nov 13 Astria Therapeutics to Present at Upcoming Jefferies London Healthcare Conference
    Oct 30 Astria Therapeutics to Present at Upcoming Canadian Society of Allergy and Clinical Immunology Annual Scientific Meeting
    Oct 21 Astria Therapeutics to Present at Upcoming American College of Allergy, Asthma, and Immunology Annual Scientific Meeting
    Oct 18 Companies Like Astria Therapeutics (NASDAQ:ATXS) Are In A Position To Invest In Growth
    Oct 16 European Commission Grants Orphan Medicinal Product Designation for Navenibart, Astria Therapeutics’ Investigational Therapy for the Treatment of Hereditary Angioedema
    Sep 30 Astria Therapeutics Receives FDA Orphan Drug Designation for Navenibart (STAR-0215) for the Treatment of Hereditary Angioedema
    Sep 27 Astria Therapeutics to Present at Upcoming Global Angioedema Forum
    Sep 19 Astria Therapeutics to Present at Upcoming European Academy of Dermatology and Venerology Congress
    See more ATXS news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 16.9
    52 Week Low 4.44
    Average Volume 327,303
    200-Day Moving Average 11.32
    50-Day Moving Average 11.31
    20-Day Moving Average 11.09
    10-Day Moving Average 10.52
    Average True Range 0.77
    RSI (14) 35.90
    ADX 18.74
    +DI 14.92
    -DI 29.40
    Chandelier Exit (Long, 3 ATRs) 10.20
    Chandelier Exit (Short, 3 ATRs) 10.92
    Upper Bollinger Bands 12.99
    Lower Bollinger Band 9.20
    Percent B (%b) 0.1
    BandWidth 34.09
    MACD Line -0.50
    MACD Signal Line -0.25
    MACD Histogram -0.2434
    Fundamentals Value
    Market Cap 523.7 Million
    Num Shares 54.7 Million
    EPS -2.12
    Price-to-Earnings (P/E) Ratio -4.52
    Price-to-Sales 0.00
    Price-to-Book 9.36
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 10.46
    Resistance 3 (R3) 10.43 10.11 10.31
    Resistance 2 (R2) 10.11 9.88 10.12 10.26
    Resistance 1 (R1) 9.84 9.75 9.68 9.87 10.21
    Pivot Point 9.52 9.52 9.44 9.54 9.52
    Support 1 (S1) 9.26 9.30 9.10 9.29 8.95
    Support 2 (S2) 8.94 9.16 8.95 8.90
    Support 3 (S3) 8.67 8.94 8.85
    Support 4 (S4) 8.70